CVS Health (NYSE:CVS) Lifted to Strong-Buy at UBS Group

CVS Health (NYSE:CVS) was upgraded by investment analysts at UBS Group from an “outperform” rating to a “strong-buy” rating in a note issued to investors on Thursday, January 4th, The Fly reports.

CVS has been the topic of several other research reports. Loop Capital decreased their price target on shares of CVS Health from $83.00 to $73.00 and set a “hold” rating on the stock in a research note on Tuesday, November 7th. Needham & Company LLC upped their target price on shares of CVS Health from $85.00 to $88.00 and gave the company a “buy” rating in a research report on Tuesday, January 2nd. Jefferies Group decreased their target price on shares of CVS Health from $86.00 to $76.00 and set a “hold” rating on the stock in a research report on Tuesday, November 7th. Deutsche Bank initiated coverage on shares of CVS Health in a research report on Monday, December 4th. They set a “buy” rating and a $90.00 target price on the stock. Finally, Raymond James Financial reiterated a “buy” rating on shares of CVS Health in a report on Monday, December 4th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $86.66.

Shares of CVS Health (NYSE CVS) traded down $0.24 during mid-day trading on Thursday, hitting $78.78. 7,098,200 shares of the stock were exchanged, compared to its average volume of 9,051,855. CVS Health has a 12-month low of $66.45 and a 12-month high of $84.72. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.55 and a current ratio of 1.05. The company has a market cap of $79,800.00, a P/E ratio of 16.28, a price-to-earnings-growth ratio of 1.25 and a beta of 0.90.

CVS Health (NYSE:CVS) last released its earnings results on Monday, November 6th. The pharmacy operator reported $1.50 earnings per share for the quarter, beating analysts’ consensus estimates of $1.49 by $0.01. CVS Health had a net margin of 2.77% and a return on equity of 16.96%. The company had revenue of $46.18 billion for the quarter, compared to analysts’ expectations of $46.17 billion. During the same quarter in the previous year, the company earned $1.64 EPS. CVS Health’s revenue for the quarter was up 3.5% on a year-over-year basis. sell-side analysts expect that CVS Health will post 5.89 earnings per share for the current fiscal year.

In other CVS Health news, EVP Lisa Bisaccia sold 29,445 shares of the firm’s stock in a transaction on Thursday, December 21st. The shares were sold at an average price of $75.00, for a total value of $2,208,375.00. Following the completion of the transaction, the executive vice president now owns 15,556 shares of the company’s stock, valued at $1,166,700. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 0.61% of the company’s stock.

Several large investors have recently added to or reduced their stakes in CVS. KCS Wealth Advisory acquired a new stake in CVS Health during the fourth quarter valued at $355,000. CMH Wealth Management LLC grew its position in CVS Health by 131.1% during the fourth quarter. CMH Wealth Management LLC now owns 30,425 shares of the pharmacy operator’s stock valued at $2,237,000 after buying an additional 17,260 shares during the period. Hexavest Inc. grew its position in CVS Health by 18.2% during the fourth quarter. Hexavest Inc. now owns 1,329,539 shares of the pharmacy operator’s stock valued at $96,392,000 after buying an additional 204,618 shares during the period. Benson Investment Management Company Inc. acquired a new stake in CVS Health during the fourth quarter valued at $2,677,000. Finally, Lathrop Investment Management Corp grew its position in CVS Health by 4.7% during the fourth quarter. Lathrop Investment Management Corp now owns 150,786 shares of the pharmacy operator’s stock valued at $10,932,000 after buying an additional 6,831 shares during the period. Hedge funds and other institutional investors own 81.69% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “CVS Health (NYSE:CVS) Lifted to Strong-Buy at UBS Group” was first posted by BBNS and is the sole property of of BBNS. If you are accessing this story on another domain, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The legal version of this story can be accessed at https://baseballnewssource.com/markets/cvs-health-cvs-upgraded-at-ubs-group/1818811.html.

CVS Health Company Profile

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

The Fly

Analyst Recommendations for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.